vv Journal of Gynecological Research and Obstetrics CC By 061 Citation: Hayashi T, Ichimura T, Kasai M, Kanai Y, Ando H, et al. (2017) Biological Analyses for Characterization of the Uterine Sarcoma Using Mouse Model. J Gynecol Res Obstet 3(2): 061-063. DOI: http://dx.doi.org/10.17352/jgro.000040 Clinical Group http://dx.doi.org/10.17352/jgro.000040 DOI Abstract Uterine sarcomas are neoplastic malignancies that typically arise in tissues of a mesenchymal origin in uterine body. The identification of novel molecular mechanisms leading to sarcoma formation, and the establishment of new therapies and biomarkers has been hampered by several critical factors. Uterine leiomyosarcoma (U-LMS), which is the most common sarcoma, is rarely observed in clinical settings, with fewer than 15,000 new cases being diagnosed each year in the United States. Another complicating factor is that U-LMS are extremely heterogeneous as they arise in a multitude of tissues from many different cell lineages. The scarcity of clinical samples coupled with its inherent heterogeneity creates a challenging experimental environment for clinicians and scientists. Faced with these challenges, there have been extremely limited advances in treatment options available to patients with U-LMS compared with those for patients with other malignant tumors. In order to glean insight into the pathobiology of U-LMS, scientists are now using mouse models whose genomes have been specifically tailored to carry gene deletions, gene amplifications, and point mutations commonly observed in human soft tissue sarcomas. The use of these model organisms has been successful in increasing our knowledge and understanding of how alterations in relevant oncogenic, tumor suppressive, and signaling pathways directly impact sarcomagenesis. It is the aim of many in the biological community that the use of these genetically modified mouse models will serve as powerful in vivo tools to further our understanding of sarcomagenesis and potentially identify novel biomarkers and develop therapeutic strategies. Short Communication Biological Analyses for Characterization of the Uterine Sarcoma Using Mouse Model Takuma Hayashi 1,7,8 *, Tomoyuki Ichimura 2 , Mari Kasai 2 , Yae Kanai 3,9 , Hirofumi Ando 1 , Koichi Ida 1 , Nobuo Yaegashi 4 , Susumu Tonegawa 5 and Ikuo Konishi 6 1 Department of Obstetrics and Gynecology, Shinshu University Graduate School of Medicine, Nagano, Japan 2 Department of Obstetrics and Gynecology, Osaka City University School of Medicine, Osaka, Japan 3 Department of Pathology, Keio University, School of Medicine, Tokyo Japan 4 Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Miyagi, Japan 5 Picower Institute for Learning and Memory and Massachusetts Institute of Technology, MA, USA 6 National Hospital Organization Kyoto Medical Center, Kyoto, Japan 7 Promoting Business using Advanced Technology, Japan Science and Technology Agency (JST), Tokyo, Japan 8 Sigma-Aldrich Collaboration Laboratory, Rehovot, Israel 9 The International Human Epigenome Consortium (IHEC) and CREST, Japan Science and Technology Agency (JST), Saitama, Japan Dates: Received: 15 May, 2017; Accepted: 24 May, 2017; Published: 25 May, 2017 *Corresponding author: Takuma Hayashi, Department of Obstetrics and Gynecology, Shinshu University, Graduate School of Medicine, 3-1-1, Asahi, Matsu- moto, Nagano, Japan, 390-8621, Tel: 81-263-37-2614; E-mail: Keywords: Leiomyosarcoma; LMP2; Tumour protein 53 (TP53); Retinoblastoma (RB) https://www.peertechz.com Introduction Uterine sarcomas comprise a group of rare tumors with differing tumor biology, natural history and response to treatment. Clinical diagnosis is often made following surgical approach for presumed benign disease. Currently pre-operative imaging does not reliably distinguish between benign leiomyomas and other malignant pathology. Uterine leiomyosarcoma (U-LMS) is the most common sarcoma but other subtypes include endometrial stromal sarcoma (low grade and high grade), undifferentiated uterine sarcoma and adenosarcoma. U-LMSs are a rare malignant mesenchymal tumor with less than 15,000 new cases being diagnosed each year in the United States. Though rare, U-LMSs are highly debilitating malignancies as they are often associated with significant morbidity and mortality. U-LMSs are biologically very heterogeneous, as evidenced by these tumors arising from a plethora of different tissues and cell types. They are classically defined by their tissue of origin and are additionally stratified by their histopathology or patient’s age at diagnosis [1]. While these classifications have proven useful, modern pathobiological and clinical techniques have the ability to further stratify soft tissue sarcomas based on their genetic profiles [2]. Cytogenetic and karyotype analyses have revealed two divergent genetic profiles in U-LMSs. The first and most simple genetic profiles are the observation of translocation events in U-LMSs with an otherwise normal diploid karyotype. On the other hand, most U-LMSs display a more complex genetic phenotype, suggesting that genomic instability plays an important role in many U-LMSs. Aim is to understand the molecular mechanisms of human U-LMS, which may lead to identification of new diagnostic candidates or therapeutic targets against human U-LMS. IFN-Ȗ-inducible factor, LMP2/ȕ1i correlates to uterine mesenchymal transformation The proteasome is a key regulator of cellular protein